A small study involving 24 participants found that psilocybin therapy was safe and effective up to one year following administration. More research using larger sample sizes is needed to further clarify efficacy and safety. A study on the safety and efficacy of psilocybin-assisted therapy in a therapeutic setting in 24 participants with major depressive disorder found that the hallucinogen...
3,4-methylenedioxymethamphetamine (MDMA) holds promise to once again become a therapeutic tool. After 16 years of preliminary clinical trials, the Food and Drug Administration (FDA) in late August gave expedited approval for multiple phase 3 trials of 3,4-methylenedioxymethamphetamine (MDMA) as a potential "breakthrough therapy" for treatment of posttraumatic stress disorder (PTSD). The complex...